

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: Based on PCT/JP2003/015836
Filed: Intl. Filing 11 DECEMBER 2003
1st Inventor: Shuji HINUMA
For: Novel Use of EDG Receptors
Atty. Dkt. No. 3127 US0P

Art Unit: tba
Examiner: tba
Allowed:
Batch:
Paper No.:

Information Disclosure Statement

MAIL STOP PCT
P.O. Box 1450
Commissioner for Patents
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, 1.97 and 1.98, Applicants request consideration of the references listed on the attached Forms PTO/SB/08A and PTO/SB/08B. A legible copy of each listed reference is herewith being provided to the Examiner.

This Information Disclosure Statement is being submitted within 3 months of the filing date of the above-identified application, and before the mailing date of the first Office Action on the merits, thus, no certification or fee is required.


Applicants respectfully request that the listed documents be considered by the Examiner and formally be made of record in the present application and that an initialed copy of the attached form PTO/SB/08A be returned in accordance with MPEP §609.

Should the Examiner believe that a conference with Applicants' attorney would advance prosecution of this application, the Examiner is respectfully requested to call Applicants' attorney.

Dated: 4/6/2005

(847) 383-3372
(847) 383-3391

Respectfully submitted,



Mark Chao, Ph.D., Reg. No. 37,293
Elaine M. Ramesh, Ph.D., Reg. No. 43,032
Attorney for Applicants
Customer No. 23115

Takeda Pharmaceuticals North America, Inc.
Intellectual Property Department
475 Half Day Road
Lincolnshire, IL 60069 USA

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	4
-------	---	----	---

Complete if Known

Application Number	Based on PCT/JP2003/015836
Filing Date	Intl Filing 11 DECEMBER 2003
First Named Inventor	Shuji HINUMA
Art Unit	tba
Examiner Name	tba
Attorney Docket Number	3127 US0P

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	A3	WO 01/03739 A1 - Abstract	01/18/2001	Ono Pharmaceutical Co.		
	A4	WO 02/077642 A1 - Abstract	10/03/2002	Nippon Shinyaku Co., Ltd.		
	A5	EP 1195165 A1	04/10/2002	Ono Pharmaceutical Co.		
	A6	WO 99/33972	07/08/1999	Allelix Biopharmaceuticals		
	A7	JP 2002-360118 - Abstract	12/17/2002	Nippon Shinyaku Co, Ltd.		
	A8	WO 03/051876 A1 - Abstract	06/26/2003	Japan Tobacco Inc.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

JC09 Rec'd PCT/PTO 06 JUN 2005

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Number	Based on PCT/JP2003/015836
Filing Date	Intl Filing 11 DECEMBER 2003
First Named Inventor	Shuji HINUMA
Art Unit	tba
Examiner Name	tba
Attorney Docket Number	3127 US0P

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ *Number ⁴ *Kind Code ⁵ (if known)				
	A9	WO 2004/002430 A2	01/08/2004	Combinatorx Incorporated		
	A10	WO 03/024402 A2	03/27/2003	The Univ. of Tenn. Research		
	A11	WO 03/073986 A2	09/12/2003	Merck & Co., Inc.		
	A12	WO 02/29001 A2	04/11/2002	U of Virginian Patent Fdn.		
	A13	WO 99/33972	08/08/1999	Allelix Biopharmaceuticals		
	A14	WO 03/062252 A1	07/31/2003	Merck & Co., Inc.		

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

10/537 676

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number	Based on PCT/JP2003/015836
Filing Date	Intl Filing 11 DECEMBER 2003
First Named Inventor	Shuji HINUMA
Art Unit	tba
Examiner Name	tba
Attorney Docket Number	3127 US0P

(Use as many sheets as necessary)

Sheet	3	of	4
-------	---	----	---

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ *Number ⁴ *Kind Code ⁵ (if known)				
	A15	WO 03/062248 A2	07/31/2003	Merck & Co., Inc.		
	A16	WO 03/099765 A1-Abstract	12/04/2003	Ono Pharmaceutical Co.		

Date
Considered

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	Based on PCT/JP2003/015836
		Filing Date	Intl Filing 11 DECEMBER 2003
		First Named Inventor	Shuji HINUMA
		Art Unit	tba
		Examiner Name	tba
Sheet	4	of	4
		Attorney Docket Number	3127 US0P

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A17	YOSHIO TAKADA, et al, "Cloning of cDNAs Encoding G Protein-Coupled Receptor Expressed in Human Endothelial Cells Exposed to Fluid Shear Stress", Biochemical and Biophysical Research Communications, (1997), pp. 737-741, Vol. 240.	
	A18	SONGZHU AN, et al., "Molecular Cloning of the Human Edg2 Protein and Its Identification as a Functional Cellular Receptor for Lysophosphatidic Acid", Biochemical and Biophysical Research Communications, (1997), pp. 619-622, Vol. 231.	
	A19	MENG-JER LEE, et al., "Vascular Endothelial Cell Adherens Junction Assembly and Morphogenesis Induced by Sphingosine-1-Phosphate", Cell, (1999), pp. 301-312, Vol. 99.	
	A20	FANG WANG, et al., "Sphingosine 1-Phosphate Stimulates Cell Migration through a Gi-coupled Cell Surface Receptor", The Journal of Biological Chemistry, (1999), pp. 35343-35350, Vol. 274, No. 50.	
	A21	CHIYOKO N. INOUE, et al., "Lysophosphatidic Acid and Mesangial Cells: Implications for Renal Diseases", Clinical Science, (1999), pp. 431-436, Vol. 96.	
	A22	NORIO HANFUSA, et al., "Sphingosine 1-Phosphate Stimulates Rat Mesangial Cell Proliferation from Outside the Cells", Nephrology dialysis Transplantation, (2002), pp. 580-586, Vol. 17.	
	A23	S. KATSUMA, et al., "Genomic Analysis of a Mouse Model of Immunoglobulin A Nephropathy Reveals an Enhanced PDGF-EDG5 Cascade", The Pharmacogenomics Journal, (2001), pp. 211-217, Vol. 1.	
	A24	Y. KOIDE, et al., "Development of Novel EDG3 Antagonists Using a 3D Database Search and Their Structure-Activity Relationships, J. Med. Chem., (2002), pp. 4629-4638, Vol. 45.	
	A25	H. OHTA, et al., "Ki16425, a Subtype-Selective Antagonist for EDG-Family Lysophosphatidic Acid Receptors", Molecular Pharmacology, (2003), pp. 994-1105, Vol. 64, No. 4.	
	A26	DONG-SOON IM, et al., "Characterization of the Human and Mouse Sphingosine 1-Phosphate Receptor, S1P5 (Edg-8): Structure-Activity Relationship of Sphingosine 1-Phosphate Receptors", Biochemistry, (2001), pp. 14053-14060, Vol. 40.	

Examiner Signature	Date Considered
---------------------------	------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.